Sept. 5, 2022, China, HANGZHOU — CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy. [Read more…]
American Academy of Stem Cell Physicians To Host Fall Conference in Chicago on October 28-30, 2022
Workshops to be held on Fluoroscopic Intra Discal Procedure of the Lumbar Spine, Neuroregenesis, Mini Lipo Aspiration Techniques, and Knee, Shoulder & Spine Techniques.
Cord Blood Industry Consolidation Escalates in 2022
The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.
Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half.
Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America. [Read more…]
Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy
MILPITAS, Calif. — Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space. [Read more…]
Laverock Therapeutics founded to develop the next generation of programmable cell therapies
31st August 2022, Stevenage, UK — Laverock Therapeutics Ltd was founded to develop a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the Company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of an experienced senior management team. [Read more…]
